That\u2019s why when Moderna got the \u201crefusal-to-file\u201d letter this month<\/a>, signed by head vaccine regulator Vinay Prasad, the company was blindsided, Hoge said. \u201cThe letter, refusing to even review, really does feel like it came out of the blue to us.\u201d<\/p>\n Prasad took issue with the comparator arm Moderna used in its trial. STAT reported<\/a> that staff in the vaccine office was ready to review the application, but Prasad overruled them.<\/p>\n Hoge also spoke about what Moderna now plans to do going forward, how this decision will affect the rest of the biopharma industry, and much more.<\/p>\n The conversation has been lightly edited for clarity. \t\t\tModerna Hoge: No. And the letter, refusing to even review, really does feel like it came out of the blue to us. These are incredibly large and complicated development programs. You know this, but it\u2019s very risky to try and bring forward a medicine. And so we were investing almost a billion dollars in that Phase 3. So over five years of working closely with the FDA, we wanted to make sure the trial we were running was acceptable to them.<\/p>\n STAT+ Exclusive Story<\/p>\n Already have an account? Log in<\/a><\/p>\n \t\t\t \t\t\t\t\t \t\t\t\tThis article is exclusive to STAT+ subscribers Already have an account? Log in<\/a><\/p>\n \t\t\t\t\t\tIndividual plans<\/p>\n \t\t\t\t\t\tGroup plans<\/p>\n
Matthew Herper: Moderna released text of a communication from the FDA where the FDA said Moderna\u2019s choice of a comparator in this trial, the standard flu vaccine, was acceptable. But the FDA was also pretty clear it would have preferred a high-dose vaccine in older seniors. Did the FDA ever change that guidance to Moderna before your trial started, before it was completed, before the review? Had you heard this before this letter?<\/p>\n
\n\t\t\tMore on Moderna and the FDA<\/p>\n![\"STAT+\"\/](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/12\/1765280600_844_stat-plus-breaker-bg.png\")
<\/p>\n
\n\t\t\t\t\t\t![\"STAT+\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\"){kind=logo}
\n\t\t\t\t\t<\/a><\/p>\n
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n